Title:Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins
Volume: 19
Issue: 13
Author(s): Qun Zhou*
Affiliation:
- Protein Engineering, Biologics Research, Sanofi, Framingham, MA, 01701,United States
Keywords:
Glycan-binding proteins, lectins, antibodies, clinical development, inflammation, autoimmune diseases, hematological
malignancies.
Abstract: Background: Glycan-binding proteins are widely distributed in human and play an essential
role in biological processes. Their involvements in inflammatory and immune responses make it
increasingly likely that the glycan-binding proteins may represent valuable therapeutic targets.
Objective: The current review aims to provide information on recent advancements in clinical developments
of antibodies against glycan-binding proteins as potential targets.
Results and Conclusion: There are several therapeutic antibodies being developed targeting glycanbinding
proteins, including CD22, CD33, DEC-205, and CD62P, for different diseases. The clinical
investigations demonstrated benefits of treatments with one antibody-drug conjugate against CD22 being
approved by the regulatory agencies. The recent progresses in clinical developments of these antibodies
have provided great promises in therapeutic targeting of more glycan-binding proteins for treating
multiple diseases, including inflammation, autoimmune diseases, and hematological malignancies.
